The ability to find non-invasive biomarkers to differentiate between tauopathy and TDP-43 pathology is important as proteinopathy-targeted therapies are being developed (Liscic et al., 2020; Yang et al., 2020). Here, TARDBP is linked to proteostasis deficiencies.